The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what RFK Jr.'s peptide push could unleash risky drugs STAT First Opinion GHK Cu Peptide Therapy Brea, CA Orange County RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban Ars Technica 7 FDA Headlines You Missed in January 2026 HCPLive FDA approval awaited this month . : r biotech_stocks